1. Home
  2. BCAB vs AAME Comparison

BCAB vs AAME Comparison

Compare BCAB & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • AAME
  • Stock Information
  • Founded
  • BCAB 2007
  • AAME 1968
  • Country
  • BCAB United States
  • AAME United States
  • Employees
  • BCAB N/A
  • AAME N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • AAME Life Insurance
  • Sector
  • BCAB Health Care
  • AAME Finance
  • Exchange
  • BCAB Nasdaq
  • AAME Nasdaq
  • Market Cap
  • BCAB 27.0M
  • AAME 27.1M
  • IPO Year
  • BCAB 2020
  • AAME N/A
  • Fundamental
  • Price
  • BCAB $0.45
  • AAME $1.81
  • Analyst Decision
  • BCAB Buy
  • AAME
  • Analyst Count
  • BCAB 2
  • AAME 0
  • Target Price
  • BCAB $1.00
  • AAME N/A
  • AVG Volume (30 Days)
  • BCAB 538.8K
  • AAME 19.2K
  • Earning Date
  • BCAB 05-06-2025
  • AAME 05-20-2025
  • Dividend Yield
  • BCAB N/A
  • AAME 1.10%
  • EPS Growth
  • BCAB N/A
  • AAME N/A
  • EPS
  • BCAB N/A
  • AAME N/A
  • Revenue
  • BCAB $11,000,000.00
  • AAME $188,227,000.00
  • Revenue This Year
  • BCAB N/A
  • AAME N/A
  • Revenue Next Year
  • BCAB N/A
  • AAME N/A
  • P/E Ratio
  • BCAB N/A
  • AAME N/A
  • Revenue Growth
  • BCAB N/A
  • AAME 0.77
  • 52 Week Low
  • BCAB $0.24
  • AAME $1.25
  • 52 Week High
  • BCAB $3.53
  • AAME $1.99
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 59.13
  • AAME 68.89
  • Support Level
  • BCAB $0.44
  • AAME $1.52
  • Resistance Level
  • BCAB $0.58
  • AAME $1.60
  • Average True Range (ATR)
  • BCAB 0.06
  • AAME 0.12
  • MACD
  • BCAB 0.00
  • AAME 0.03
  • Stochastic Oscillator
  • BCAB 64.11
  • AAME 90.38

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

Share on Social Networks: